Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer
Go back to Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer| VERASTEM SHS (NASDAQ: VSTM) | Delayed: 7.55 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $7.55 | 52 Week High | $2.43 | |||
| Open | $7.55 | 52 Week Low | $1.05 | |||
| Day High | $7.55 | P/E | N/A | |||
| Day Low | $7.55 | EPS | $-1.79 | |||
| Volume | 500 | |||||
